08/01/14 - 11:11 AM EDT
In order to enroll the remaining 648 patients into the Multikine study by the end of 2015, Cel-Sci needs to average 40.5 patients per month, or 121.5 patients per quarter.READ FULL POST
07/29/14 - 10:26 AM EDT
Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.READ FULL POST
07/28/14 - 12:34 PM EDT
Like Galena BioPharma and The DreamTeam Group, Galectin is also paying for a promotional campaign designed to entice retail investors into buying its stock.READ FULL POST
07/28/14 - 10:56 AM EDT
Express Scripts and CVS Caremark are the largest and second-largest pharmacy benefits managers in the U.S. Both have been aggressive with efforts to rein in ever-escalating drug prices.READ FULL POST
07/28/14 - 09:44 AM EDT
AcelRx believes it can gather all the requested information and re-submit Zalviso to the FDA before the end of the year.READ FULL POST
07/25/14 - 11:30 AM EDT
MannKind must report second-quarter financials before the end of the second week in August, which sets a quasi-deadline for Afrezza partner plans.READ FULL POST
07/24/14 - 09:21 AM EDT
Sarepta terminates Chief Scientific Officer Art Krieg. Here's what I've learned about why he was fired.READ FULL POST
07/23/14 - 05:44 PM EDT
In its first two quarters on the market, Sovaldi, a pill used to treat hepatitis C, has delivered $5.8 billion in revenue to Gilead. Remarkable.READ FULL POST
07/23/14 - 12:26 PM EDT
Puma is why so many investors love to speculate on biotech stocks. A contrarian trade against a heavily expected outcome can return a fortune.READ FULL POST
07/23/14 - 10:17 AM EDT
Inovio's analysis of the VGX-3100 study omits an unknown number of patients, calling the results into question.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.